Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) have earned a consensus rating of “Hold” from the seventeen brokerages that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $54.55.

PCRX has been the subject of several recent research reports. Zacks Investment Research lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Wedbush restated an “outperform” rating and set a $87.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 21st. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 target price on shares of Pacira Pharmaceuticals in a research report on Monday, May 15th. BidaskClub upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Mizuho reiterated a “buy” rating and issued a $54.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th.

Pacira Pharmaceuticals (NASDAQ PCRX) opened at 35.75 on Tuesday. The company has a 50 day moving average of $42.75 and a 200-day moving average of $45.28. Pacira Pharmaceuticals has a 52-week low of $29.95 and a 52-week high of $58.95. The stock’s market capitalization is $1.44 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.06. The firm had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.21 EPS. Equities research analysts anticipate that Pacira Pharmaceuticals will post ($0.12) EPS for the current year.

In other news, SVP Scott Braunstein sold 768 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $43.32, for a total transaction of $33,269.76. Following the completion of the transaction, the senior vice president now owns 9,982 shares in the company, valued at approximately $432,420.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Lauren Bullaro Riker sold 601 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $43.32, for a total transaction of $26,035.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,869 shares of company stock valued at $1,590,276. Insiders own 6.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its position in Pacira Pharmaceuticals by 5.2% in the second quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock valued at $261,000 after buying an additional 270 shares during the period. Ameritas Investment Partners Inc. raised its position in Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after buying an additional 302 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in Pacira Pharmaceuticals by 12.2% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after buying an additional 303 shares during the period. Renaissance Technologies LLC raised its position in Pacira Pharmaceuticals by 1.6% in the fourth quarter. Renaissance Technologies LLC now owns 25,200 shares of the company’s stock valued at $814,000 after buying an additional 400 shares during the period. Finally, Denver Investment Advisors LLC raised its position in Pacira Pharmaceuticals by 6.8% in the second quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock valued at $327,000 after buying an additional 435 shares during the period.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/22/pacira-pharmaceuticals-inc-pcrx-given-consensus-recommendation-of-hold-by-analysts.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.